Medical Oncology

, 30:604 | Cite as

UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

  • Jing Gao
  • Jun Zhou
  • Yanyan Li
  • Ming Lu
  • Ru Jia
  • Lin Shen
Original Paper


The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients. The genotypes of UGT1A1*6 and UGT1A1*28 were analyzed by PCR amplification and Sanger sequencing in 276 advanced colorectal cancer patients receiving irinotecan-containing chemotherapy. The influences of UGT1A1*6/*28 polymorphisms on severe diarrhea and neutropenia were analyzed. The overall incidence of UGT1A1*6 and UGT1A1*28 variants was 35.5 % (GA: 28.6 %; AA: 6.9 %) and 21.0 % (TA6/TA7: 19.9 %; TA7/TA7: 1.1 %) in our cohort, respectively. A total of 16 patients (5.8 %, 16/276) had severe diarrhea and 56 patients (20.3 %, 56/276) had severe neutropenia. Neither UGT1A1*6 nor UGT1A1*28 variants were associated with severe diarrhea; however, either UGT1A1*6 (P = 0.001) or UGT1A1*28 (P = 0.029) variants were significantly associated with severe neutropenia. No differences were found between severe toxicities and clinical response in this study. Compared to western countries, Chinese patients had a distinct frequency of UGT1A1*6 or UGT1A1*28 genotypes. Both UGT1A1*6 and UGT1A1*28 variants were closely associated with irinotecan-induced severe neutropenia, but not diarrhea.


UGT1A1 Polymorphism Irinotecan Diarrhea Neutropenia 



This work was supported by National Natural Science Foundation of China (No. 81172110), National High Technology Research and Development Program (No. 2006AA 02A 402-B02, 2012AA 02A 504). We thank Dr. Jiping Yue (Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France) for critical reading of this manuscript.

Conflict of interest



  1. 1.
    Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009;27:2653–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Andreetta C, Puppin C, Minisini A, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol. 2009;20:265–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1:65–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Ohyanagi F, Horiike A, Okano Y, et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2008;61:503–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamamoto K, Kokawa K, Umesaki N, et al. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: japanese gynecologic oncology group study. Oncol Rep. 2009;21:1005–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010;20:240–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343:905–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6.PubMedGoogle Scholar
  10. 10.
    Desai AA, Innocenti F, Ratain MJ. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003;22:6621–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Martinez-Balibrea E, Abad A, Martínez-Cardús A, et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer. 2010;103:581–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112:1932–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009;10:733–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Schulz C, Heinemann V, Schalhorn A, et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol. 2009;15:5058–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Glimelius B, Garmo H, Berglund A, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 2011;11:61–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Park SR, Kong SY, Rhee J, et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol. 2011;22:890–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Takano M, Kato M, Yoshikawa T, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009;76:315–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17:497–504.CrossRefPubMedGoogle Scholar
  19. 19.
    Sunakawa Y, Ichikawa W, Fujita K, et al. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2011;68:279–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Shulman K, Cohen I, Barnett-Griness O, et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer. 2011;117:3156–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C > A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007;98:1461–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol. 2011;41:477–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Han JY, Lim HS, Shin ES, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer. 2008;59:69–75.CrossRefPubMedGoogle Scholar
  24. 24.
    Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Stewart CF, Panetta JC, O’Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007;25:2594–600.CrossRefPubMedGoogle Scholar
  26. 26.
    Marcuello E, Páez D, Paré L, et al. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer. 2011;105:53–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011;102:1868–73.CrossRefPubMedGoogle Scholar
  28. 28.
    Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Cortejoso L, García MI, García-Alfonso P, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013. doi: 10.1007/s00280-013-2145-6.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jing Gao
    • 1
  • Jun Zhou
    • 1
  • Yanyan Li
    • 1
  • Ming Lu
    • 1
  • Ru Jia
    • 1
  • Lin Shen
    • 1
  1. 1.Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)Peking University, Cancer Hospital & InstituteBeijingChina

Personalised recommendations